A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert

Inclusion Criteria: * Had prior bilateral treatment and completion, through a minimum of week 12, of the OTX-16-002 trial * Are informed of the nature of the study and subject is able to comply with study requirements and visit schedule for one year * Have provided written informed consent, approved by the appropriate Institutional Review Board Exclusion Criteria: * Had more than 1 replacement, per eye, during participation in the OTX-16-002 trial * Had punctal or canaliculi related adverse events during the OTX-16-002 trial which required discontinuation (e.g., canaliculitis) * Used prohibited medications during the OTX-16-002 study, or the period between OTX-16-002 and this trial (with the exception of short term medication used to treat an adverse event or rescue therapy) * Missed more than 2 visits during participation in the OTX-16-002 trial